NASDAQ$MBRX
Moleculin Biotech Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Moleculin Biotech Inc reported a net loss of $12.8 million for Q1 2026 driven by increased R&D spending on its MIRACLE trial.
The company continued advancing its lead candidate Annamycin in the pivotal Phase 2B/3 MIRACLE trial for relapsed/refractory AML with no revenues recorded. Operating expenses rose to $7.9 million primarily from clinical trial and drug development costs. Cash position improved to $10.3 million following warrant inducement financing completed in February 2026.
- Net loss widened to $12.8 million from $5.9 million year-over-year due to higher R&D and non-cash warrant accounting items.
- MIRACLE trial enrollment reached 56 subjects by early May 2026 with interim unblinding of 45-subject data expected before June 30 2026.
- Cash and cash equivalents increased to $10.3 million after raising $8.3 million gross via warrant exercises and inducements.
- Company maintains focus on Annamycin development with plans for additional pancreatic cancer and pediatric AML trials in 2026-2027.
Headline financials
Revenue & EPS history
Moleculin · Revenue · Quarterly
$0
Forward guidance
Management expects interim unblinded data from the first 45 subjects in the MIRACLE trial in mid-2026 and plans to initiate additional Annamycin trials in pancreatic cancer and pediatrics.
Tailwinds
- Preliminary blinded CRc rate exceeding 40% in MIRACLE trial supports continued enrollment momentum.
- No cardiotoxicity observed across 90 patients in pooled Annamycin data.
- Additional $0.8 million raised post-quarter via ATM facility.
Headwinds
- Accumulated deficit increased to $218.8 million.
- Cash runway extends only into Q3 2026 requiring additional financing.
- Ongoing Nasdaq compliance monitoring after prior deficiencies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2026
-1.2%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-5.3%
Avg return
30 days after
32%
13 / 41 earnings
Positive
+28.1%
Q4 2019
Best reaction
-20.8%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.8% | +9.8% | — | |
| Q4 2025 | +0.0% | +20.9% | +17.5% | |
| Q3 2025 | -4.4% | -3.5% | -56.1% | |
| Q2 2025 | -4.0% | -11.7% | -46.1% | |
| Q1 2025 | -8.2% | -1.3% | -35.3% | |
| Q4 2024 | -2.8% | -3.7% | -12.8% | |
| Q3 2024 | +3.5% | +6.3% | +3.9% | |
| Q2 2024 | -5.1% | +2.1% | +3.4% | |
| Q1 2024 | +1.9% | +6.7% | -9.2% | |
| Q4 2023 | -20.8% | -16.4% | -29.9% | |
| Q3 2023 | +1.9% | +9.3% | -2.4% | |
| Q2 2023 | -1.3% | -7.5% | -32.7% | |
| Q1 2023 | -14.4% | -21.7% | -23.1% | |
| Q4 2022 | -1.9% | -7.8% | -24.0% | |
| Q3 2022 | +5.1% | +6.1% | +48.6% | |
| Q2 2022 | +9.3% | +3.7% | -12.3% | |
| Q1 2022 | +1.6% | +9.0% | +23.0% | |
| Q4 2021 | -4.4% | -1.7% | +1.1% | |
| Q3 2021 | +0.0% | -6.5% | -5.7% | |
| Q2 2021 | -3.3% | -11.1% | -0.3% | |
| Q1 2021 | -3.8% | -2.1% | -99.7% | |
| Q4 2020 | -1.5% | -6.6% | -11.6% | |
| Q3 2020 | +2.9% | +8.5% | +14.1% | |
| Q2 2020 | -7.4% | -5.6% | -29.0% | |
| Q1 2020 | +0.0% | +0.0% | +11.2% | |
| Q4 2019 | +28.1% | +27.9% | +155.9% | |
| Q3 2019 | +0.9% | -0.9% | -4.7% | |
| Q2 2019 | +6.5% | +10.2% | +13.0% | |
| Q1 2019 | -0.8% | -5.7% | -4.9% | |
| Q4 2018 | +3.8% | -1.5% | -0.8% | |
| Q3 2018 | -3.1% | +6.1% | -3.8% | |
| Q2 2018 | +0.0% | -1.2% | +0.0% | |
| Q1 2018 | -0.6% | -0.6% | +12.1% | |
| Q4 2017 | -3.2% | -1.1% | -0.5% | |
| Q3 2017 | -0.4% | +3.7% | +5.6% | |
| Q2 2017 | -7.7% | -11.8% | -3.7% | |
| Q1 2017 | -4.7% | -4.9% | +0.0% | |
| Q4 2016 | -12.8% | -28.2% | -27.4% | |
| Q3 2016 | -2.4% | +1.7% | -50.5% | |
| Q2 2016 | -1.6% | -6.7% | -1.0% | |
| Q1 2016 | +2.3% | +5.4% | +5.2% | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro